sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Investment in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released a Form 8.3 regarding its stake in Avadel Pharmaceuticals plc, in line with the Irish Takeover Panel Act, 1997. The form provides an overview of Vanguard's ownership, highlighting its control over 5,787,815 ordinary shares, equivalent to 5.94% of Avadel's relevant securities, as of January 30, 2026.
The disclosure includes details of recent transactions. Vanguard purchased 2,868 ordinary shares at a price of 21.55 USD and sold 2,920 shares at the same price per unit. No dealings involving cash-settled or stock-settled derivatives have been reported.
No indemnity, option arrangements, or agreements affecting relevant securities have been identified, underscoring a straightforward position disclosure without additional influences impacting their investment strategy in Avadel Pharmaceuticals.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.